The discrepancies may be explained by differences in treatment strategies among the study populations, where patients with only CDKN2A/B deletion have historically been treated as “lower-grade gliomas”, while those with morphological criteria typically have received a more aggressive treatment following the Stupp regimen. This evidence concerns the gene CDKN2A and central nervous system cancer.